Riskpilot← Back to searchSign inGet full accessML Diagnostik AB
ABActiveOrg 5592651086Lupinvägen 19Medical specialists activities · NACE 8622Est. 20200 employees
Revenue 2025
SEK 0
EBITDA margin
—
+16% vs 2024
Equity ratio
82.4%
Financial strength
Net profit 2025
SEK 67K
-30% vs 2024
| Revenue | SEK 0 | — |
| EBITDA | SEK -17K | +16% |
| Net profit | SEK 67K | -30% |
| Total assets | SEK 4,8M | -2% |
| Equity | SEK 3,9M | -3% |
| Employees | 0 | — |
Legal name
ML Diagnostik AB
Org number
5592651086
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
29 juli 2020
Share capital
SEK 25 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2025-06-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Föremålet för bolagets verksamhet ska vara att bedriva konsulttjänster inom sjukvård och då främst radiologi och neuroradiologi. Bolaget skall även bedriva handel och förvaltning av fastigheter, samt investera och förvalta värdepapper.
Address
Lupinvägen 19
Email
annakarin.lonntoft@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 3 129 | 3 766 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 3 085 | 3 674 | −28 | −20 | −17 |
| Depreciation & amort. | −0 | −0 | −0 | — | — |
| EBIT | 3 085 | 3 674 | −28 | −20 | −17 |
| Net financials | — | — | 19 | 150 | 105 |
| Profit before tax | 2 315 | 3 674 | −10 | 131 | 88 |
| Tax | −496 | −758 | −1 | −35 | −21 |
| Net profit | 1 819 | 2 916 | −11 | 96 | 67 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 3 103 | 6 390 | 5 711 | 4 904 | 4 787 |
| Equity | 1 844 | 4 390 | 4 184 | 4 080 | 3 943 |
| Long-term debt | 0 | 0 | 0 | — | — |
| Short-term debt | 489 | 1 230 | 757 | 54 | 74 |
| Total debt | 489 | 1 230 | 757 | 54 | 74 |
EBITDA margin
-1652500.0%
This company
15.8%
Market median
-10458961% vs market
20212025
Equity ratio
82.4%
This company
38.2%
Market median
+116% vs market
20212025
Return on equity
1.7%
This company
18.4%
Market median
-91% vs market
20212025
Net profit margin
6686100.0%
This company
8.1%
Market median
+82544344% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
0.21×
This company
0.62×
Market median
+66% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-07-01 – 2025-06-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-07-01 – 2021-06-30
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Deputy Board Member | 2022 | |
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
| Former (1) | ||
| Board of Directors | 2022 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of ML Diagnostik AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Mats Lönntoft | Board of Directors | 0 companies |
| Johan Lönntoft | Deputy Board Member | 0 companies |
| Erika Lönntoft | Deputy Board Member | 0 companies |
| Ulla Anna-Karin Lönntoft | Board of Directors | 0 companies |